Discovery of Insulin Receptor Partial Agonists MK-5160 and MK-1092 as Novel Basal Insulins with Potential to Improve Therapeutic Index-Reference-Cited by-同舟云学术

Discovery of Insulin Receptor Partial Agonists MK-5160 and MK-1092 as Novel Basal Insulins with Potential to Improve Therapeutic Index

Published:2022-03-17 Issue:7 Volume:65 Page:5593-5605
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pissarnitski Dmitri A.¹^ORCID,Kekec Ahmet¹,Yan Lin¹,Zhu Yuping¹,Feng Danqing D.¹,Huo Pei¹,Madsen-Duggan Christina¹,Moyes Christopher R.¹,Nargund Ravi P.¹,Kelly Terri¹,Zhang Xiaoping¹,Carballo-Jane Ester¹,Gorski Judith¹,Zafian Peter²,Qatanani Mo¹,Kaarsholm Niels¹,Meng Fanyu³,Jia Xiujuan³,Lee Keun-Joong³,Wang Weixun³,Xu Sherrie¹,Hohn Michael J.¹,Iammarino Michael J.¹,McCoy Mark A.¹^ORCID,Okoh Grace A.³,Liang Yingkai²^ORCID,Hollingsworth Scott A.⁴^ORCID,Erion Mark D.¹,Kelley David E.¹,Garbaccio Robert M.¹,Zhang Amy¹,Mu James⁴,Lin Songnian¹

Affiliation:

1. Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

2. Merck & Co., Inc., West Point, Pennsylvania 19486, United States

3. Merck & Co., Inc., Rahway, New Jersey 07065, United States

4. Merck & Co., Inc., South San Francisco, California 94080, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c02073

Reference33 articles.